Crescent Biopharma FDA clears IND for CR-002
Crescent Biopharma says the FDA cleared its IND application for CR-002, a PD-L1-targeted topoisomerase inhibitor ADC for solid tumors.
Story updates
11:32:54 AM UTC
SquawkNews
Crescent Biopharma received FDA clearance of its IND for CR-002, a PD-L1-targeted topoisomerase inhibitor ADC. The Phase 1/2 APOLLO trial is expected to start in Q4 2026, with initial data anticipated in H2 2027.Material DetailsContext by AI AnalystThis is an early-stage regulatory milestone expand…